These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9402420)

  • 21. Steady-state trough plasma mibefradil concentrations and correlation to blood pressure response in hypertensive patients with chronic renal disease.
    Pordy R; Woittiez A
    Int J Clin Pharmacol Res; 1998; 18(3):105-8. PubMed ID: 9825266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rhabdomyolysis due to interaction of simvastatin with mibefradil.
    Schmassmann-Suhijar D; Bullingham R; Gasser R; Schmutz J; Haefeli WE
    Lancet; 1998 Jun; 351(9120):1929-30. PubMed ID: 9654265
    [No Abstract]   [Full Text] [Related]  

  • 23. A comparison of the safety and efficacy of mibefradil and nifedipine SR in patients with renal disease and hypertension.
    Woittiez AJ; Huysmans FT; Bailey R; Robson RA; Mion Júnior D; Villa G; Kobrin I
    Clin Nephrol; 1998 Mar; 49(3):160-6. PubMed ID: 9543597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist.
    Triggle DJ
    Am J Cardiol; 1996 Nov; 78(9A):7-12. PubMed ID: 8903279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris.
    Massie BM
    Am J Hypertens; 1998 Apr; 11(4 Pt 3):95S-102S. PubMed ID: 9607373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.
    Bakx AL; van der Wall EE; Braun S; Emanuelsson H; Bruschke AV; Kobrin I
    Am Heart J; 1995 Oct; 130(4):748-57. PubMed ID: 7572582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.
    Braun S; van der Wall EE; Emanuelsson H; Kobrin I
    J Am Coll Cardiol; 1996 Feb; 27(2):317-22. PubMed ID: 8557900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of calcium channel blockers and beta-blockers for patients with exercise-induced angina pectoris: beneficial effect of calcium channel blockers largely determined by their effect on heart rate.
    Cleophas TJ; van der Sluijs J; van der Vring JA; Daniëls MC; Holwerda KJ; Withagen AJ; Schelling A; Hendriks MG; Zwinderman AH
    J Clin Pharmacol; 1999 Jul; 39(7):738-46. PubMed ID: 10392329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
    Kobrin I; Bieska G; Charlon V; Lindberg E; Pordy R
    Cardiology; 1998; 89 Suppl 1():23-32. PubMed ID: 9570426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris.
    Alpert JS; Bakx AL; Braun S; Frishman WH; Schneeweiss A; Tzivoni D; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):20C-26C. PubMed ID: 9286850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD.
    Massie BM; Chrysant SG; Jain A; Weir M; Weiss R; Korrin I
    Clin Cardiol; 1997 Jun; 20(6):562-8. PubMed ID: 9181268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacy.
    Schneeweiss A; Kobrin I; Charlon V; Caspi A; Marmor A; Sclarovsky S; Reisin L; Schlesinger Z
    Am Heart J; 1998 Feb; 135(2 Pt 1):272-80. PubMed ID: 9489976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris.
    Alpert JS; Kobrin I; DeQuattro V; Friedman R; Shepherd A; Fenster PE; Thadani U
    Am J Cardiol; 1997 Apr; 79(8):1025-30. PubMed ID: 9114758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Capillary blood cell velocity in finger nailfold: effect of enalapril and mibefradil in patients with mild to moderate hypertension.
    Martina B; Frach B; Surber C; Drewe J; Battegay E; Gasser P
    Microvasc Res; 1999 Mar; 57(2):94-9. PubMed ID: 10049657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of calcium channel blockers in hypertension.
    Conlin PR; Williams GH
    Adv Intern Med; 1998; 43():533-62. PubMed ID: 9506192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case report: rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin.
    Wombolt DG; Jackson A; Punn R; Smith S; McCune TR; Williams PB
    J Clin Pharmacol; 1999 Mar; 39(3):310-2. PubMed ID: 10073331
    [No Abstract]   [Full Text] [Related]  

  • 37. Human vascular to cardiac tissue selectivity of L- and T-type calcium channel antagonists.
    Sarsero D; Fujiwara T; Molenaar P; Angus JA
    Br J Pharmacol; 1998 Sep; 125(1):109-19. PubMed ID: 9776350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of voltage- and use-dependent block of class A Ca2+ channels by mibefradil.
    Aczél S; Kurka B; Hering S
    Br J Pharmacol; 1998 Oct; 125(3):447-54. PubMed ID: 9806326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mibefradil release expands calcium-channel-blocker choices.
    Am J Health Syst Pharm; 1997 Sep; 54(18):2033. PubMed ID: 9377200
    [No Abstract]   [Full Text] [Related]  

  • 40. Physiologic and pathophysiologic relevance of T-type calcium-ion channels: potential indications for T-type calcium antagonists.
    Hermsmeyer K; Mishra S; Miyagawa K; Minshall R
    Clin Ther; 1997; 19 Suppl A():18-26. PubMed ID: 9385502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.